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Abstract: Early diagnosis is a key factor in improving the outcomes
of cancer patients. A greater understanding of the pre-diagnostic
patient pathways is vital yet, at present, research in this field lacks
consistent definitions and methods. As a consequence much early
diagnosis research is difficult to interpret. A consensus group
was formed with the aim of producing guidance and a checklist
for early cancer-diagnosis researchers. A consensus conference
approach combined with nominal group techniques was used. The
work was supported by a systematic review of early diagnosis
literature, focussing on existing instruments used to measure time
points and intervals in early cancer-diagnosis research. A series of
recommendations for definitions and methodological approaches
is presented. This is complemented by a checklist that early diagnosis
researchers can use when designing and conducting studies in this
field. The Aarhus checklist is a resource for early cancer-diagnosis
research that should promote greater precision and transparency in
both definitions and methods. Further work will examine whether the
checklist can be readily adopted by researchers, and feedback on the
guidance will be used in future updates.
BACKGROUND
Early diagnosis of symptomatic cancer is considered to be central
to the achievement of better outcomes (Richards, 2009). There are
national initiatives in many countries with the intention of
achieving early presentation with symptoms and early diagnosis
through more effective diagnostic routes. For example, the English
National Awareness and Early Diagnosis Initiative (NAEDI)
(Richards, 2009) is a programme of work intended to achieve
early presentation of people with symptoms to optimise clinical
practice and to improve GP access to diagnostics. Similar
important initiatives are being undertaken in a growing number
of jurisdictions (Rubin et al, 2011).
Variations in cancer survival between countries of comparable
affluence and health systems have prompted international efforts
to better understand these differences, often with a focus on the
role of early diagnosis (Coleman et al, 2011). The scope for
interventions to improve early diagnosis is wide and is receiving
significant investment by the national governments. Several
initiatives have acknowledged the need for complementary
programmes of research in order to gain better understanding of
patient and clinician behaviour and to determine the effectiveness
of the interventions they are funding (Cancer Reform Strategy,
2007; Olesen et al, 2009).
Research in this area is, however, complex; the pathways to
cancer diagnosis are often not straightforward and rarely linear
(Fisher et al, 2010; Jordan et al, 2010). The health-system context
in which research is carried out has a major influence on
individual stages of these pathways. Moreover, the published
research to date is characterised by a wide range of methodological
approaches, often poorly or imprecisely described and with little
theoretical basis. A wide range of methods have been used to
measure time points and intervals, often dictated by the available
data and resources (Neal, 2009). As a result, research findings are
frequently difficult to interpret and typically not comparable
beyond individual countries.
Furthermore, a number of different theoretical and methodolo-
gical perspectives have been applied to the definition and
measurement of time points and intervals in early diagnosis
research, and these perspectives are often not explicitly delineated
in the literature to date. Biomedical approaches predominate –
they imply a direct relationship between disease and symptoms in
the presence of illness. Other perspectives are less well-integrated
within the literature; psychological approaches distinguish
between ‘bodily changes’ (both sensations and visible changes)
and ‘symptoms’ and are interested in the processes by which one
becomes the other (Teel et al, 1997; Van Wijk and Kolk, 1997;
Bradley et al, 2001). Sociological and anthropological approaches
explore the processes by which bodily sensations are interpreted as
symptoms; they are predicated on the view that symptoms evolve
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and are interpreted through the relationship between the
individual and a given social and cultural context (Alonzo, 1984).
In the light of different purposes of the research, several
theoretical models have been developed to describe the events and
processes that underpin the pathway to symptomatic cancer
diagnosis. Influential among these are the Danish model developed
by Olesen et al (2009) and the model of pathways to treatment
(see Figure 1), a refinement by Walter et al (2011) of the Andersen
Model of Total Patient Delay.
Hence, early diagnosis research is characterised by its complex-
ity, a poorly developed set of definitions and methodological tools,
a lack of transparency in disciplinary perspectives and an absence
of a widely-accepted underlying theoretical model. Accordingly, in
order to advance the quality and consistency of studies of
diagnostic intervals in symptomatic cancer, an international
Consensus Working Group (CWG) was convened in November
2009. The purpose of the group was to formulate definitions of
key time points and to make methodological recommendations for
researchers in this field. The work was commissioned by the
Cancer Research UK and the Department of Health in England and
undertaken under the auspices of the Cancer and Primary Care
Research International (Ca-PRI) Network (http://www.ca-pri.com/).
The aim of this paper is to propose and discuss a standar-
dised set of definitions that can be used in research on early
cancer diagnosis, relating to key time points and intervals
in early diagnosis research. We also present methodological
recommendations, principally on data collection and analysis.
METHODS
We used a ‘consensus conference’ approach (Durocher, 1994) that
encompasses consensus meetings, presentations and wide circula-
tion of draft outputs for modifications and refinement. It has been
used in other fields to produce guidance for researchers
and clinicians, and is particularly useful when a wide range of
clinical, sociological, cultural and other perspectives need to be
incorporated within the guidance. We also drew on nominal group
techniques (Black et al, 1999) in our consensus meetings and in the
exchange of information in the intervals between the meetings.
Members of the CWG were drawn from a range of disciplinary
and methodological backgrounds including primary care, health-
service research, social science, psychology, epidemiology and
statistics. The CWG was supported by an international expert
reference group comprising individuals from a wide range of
clinical and methodological backgrounds. The CWG met three
times between January and November 2010 in London and Aarhus.
Each of the meetings comprised a series of presentations
addressing theoretical, empirical and methodological areas of the
project; the ensuing discussions were recorded and circulated
between meetings. Consensus was achieved through an iterative
approach, whereby proposed statements and checklists were
developed and refined in the course of these meetings and
informed by the presentations. Each element of the statement
was discussed in detail by all members of the group until
consensus was reached. The draft statement was then reviewed
by an expert reference group and further refined in the light of
their feedback.
The CWG had a close familiarity with the literature in this field.
Nevertheless, we decided to underpin this by using systematic
approaches to identify and assess relevant literature relating to
existing questionnaires and survey tools. Accordingly, we further
examined 279 included papers from a concurrent systematic review,
examining the association between outcomes and diagnostic intervals
(Neal, 2011). The inclusion criteria are shown in Box 1.
Events
Processes
Intervals
Contributing
factors
Appraisal Help-seeking Diagnostic Pre-treatment
Patient
appraisal and
self-
management
Decision to
consult HCP
and arrange
appointment
HCP
appraisal,
investigations,
referrals and
appointments
Planning and
scheduling of
treatment
Detection
of bodily
change(s)
Perceives
reason to
discuss
symptom
with HCP
First
consultation
with HCP
Diagnosis Start oftreatment
PATIENT FACTORS
(e.g. demographic, co-morbidities, psychological, social, cultural, previous experience)
HEALTHCARE PROVIDER AND SYSTEM FACTORS
(e.g. access, healthcare policy and delivery)
DISEASE FACTORS
(e.g. site, size growth rate)
Figure 1 Model of pathways to treatment (Walter et al, 2011).
Box 1 INCLUSION CRITERIA FOR SYSTEMATIC REVIEW
A study or analysis was included in the review if it fulfilled all the criteria below:
Participants: only studies or analysis that examined symptomatic cancer
patients presenting with primary cancers were included.
Aim of study: ideally, to analyse the impact of the interval between the time
of first symptomatic presentation and definitive diagnosis or treatment on a
health-related outcome.
Outcome: any study, analysing any health-related outcome, was considered
for inclusion; these include survival, diagnostic stage, treatment assignment
after diagnosis and other measures of ‘curability’. Survival was the main
outcome of interest; additionally, studies examining health-related quality-
of-life, resource-use and psychological outcomes were considered for
inclusion.
Study design: there were no restrictions on the types of study design that
were considered for inclusion.
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RESULTS
After examining the early cancer-diagnosis literature and taking
into account the extensive theoretical work in this field, the CWG
concluded that:
 There is little consistency in the definition and measurement
of key time points and intervals;
 There is little guidance for researchers in designing studies that
require the measurement of diagnostic time points and
intervals;
 Little work in this field explicitly uses a theoretical framework to
underpin definitions and measurement of diagnostic intervals;
 There is a lack of transparency and precision over methods and
instruments in early diagnosis research – typically, important
study elements, such as instrument development, are poorly
described.
Accordingly, the CWG group developed the ‘Aarhus Statement’
comprising the following series of definitions and recommendations:
Definitions
The relevance of individual time points and intervals varies
between health-care systems. Nevertheless, in an international
context, the importance of the following four time points emerged
in the Consensus Working Group discussions – we found the
representation in Figure 2, illustrating the time points and their
associated intervals, helpful:
Date of first symptom This should be defined as ‘the ‘time point
when first bodily changes and/or symptoms are noticed’.
Researchers should consider this definition to encompass several
key components: the date when the first bodily change was
noticed, the date when the first symptom was noticed, the date
when the person perceives a reason to discuss the symptom with a
health-care professional and the date when the first ‘alarm’ or
‘high-risk’ symptom was noticed. Researchers should report
clearly as to which of these definitions of first symptom has been
applied in their study.
The term ‘patient delay’ should no longer be used – instead,
‘appraisal interval’ (time taken to interpret bodily changes/
symptoms) and ‘help-seeking interval’ (time taken to act upon
those interpretations and seek help) are more helpful in describing
the ‘patient interval’ (see Figure 1). Researchers should
acknowledge in their definition as to how they have dealt with the
complexity of this time point, for example, where symptoms are
common, nonspecific, multiple or chronic, where other morbidities
coexist, and the social and health care context. It is important to
recognise that often symptoms are medically defined, and such
definitions may be inconsistent with lay-symptom definitions.
Date of first presentation This should be considered ‘the time
point at which, given the presenting signs, symptoms, history and
other risk factors, it would be at least possible for the clinician seeing
the patient to have started investigation or referral for possible
important pathology, including cancer’. There should be a demon-
strated understanding of the pattern of symptoms in the lead up to
the first presentation (e.g., frequency, chronicity and presence of
other symptoms) and whether the date has been defined from the
perspective of the health-care provider or the patient. There should
be precise descriptions of where this first presentation occurs (e.g.,
primary care, hospital department and so on).
Date of referral This should be considered ‘the time point at
which there is a transfer of responsibility from one health-care
provider to another (typically, in ‘gatekeeper’ health-care systems,
from a primary care provider to a doctor/service specialising in
cancer diagnosis and management) for further clinical diagnostic
and management activity, relating to the patient’s suspected
cancer’. Patients may be referred more than once or between
specialists; there are risks of cross-referrals within secondary care
and complex diagnostic routes (where patients ultimately receive
treatment from specialist services that are different to those
initially targeted). Researchers should use a consistent and explicit
method for dealing with such complexities. Further, referral for
investigations should be considered as a subsidiary time point that
may be of significance in some health-care settings but is not
equivalent in cases where actual responsibility for patient manage-
ment is not transferred. The service targeted in the referral should
also be described.
Date of diagnosis Studies reporting any time interval that either
begins or ends with ‘diagnosis’ should be explicit about how that
date is measured and what it actually means with respect to the
diagnostic journey within that health system. Researchers should
consult the well-developed hierarchical rationales available in the
public domain in choosing their definition of date of diagnosis –
one example is the hierarchy produced by the European Network
Total interval
System intervalDoctor intervalPatient interval
Primary care interval
Diagnostic interval Treatment interval
First
symptom
First
presentation/
clinical
appearance
First
referral to
secondary
care/refer
responsibility
First
investigation,
primary care
responsible for
the patient
First
specialist
visit
Diagnosis Treatment
start
Secondary care interval
Figure 2 An illustration of the overall milestones and time intervals in the route from first symptom until start of treatment (Olesen et al, 2009).
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of Cancer Registries (http://www.encr.com.fr/incideng.pdf) which
is shown in Box 2.
Methodological approaches
Most studies on early cancer diagnosis involve retrospective data
collection, which can be subjected to recall bias (Friedman et al,
2005). Prospective studies on patients with symptoms are often
recommended (Summerton, 2002), although they pose difficulties
due to the large numbers of participants required. Time since
diagnosis is a critical sampling issue – sampling too long after
diagnosis increases the risk of recall bias and increases the likelihood
of attrition due to death or terminal illness. Conversely, sampling too
soon after diagnosis may be insensitive and may increase the
likelihood of attrition due to ongoing active treatment (surgery,
chemotherapy and radiotherapy). The sampling method, whether
through a cancer registry, hospital-based sampling or other
mechanism, should be reproducible and thoroughly described.
Primary data collection from patients and/or providers The key
challenge in collecting data on diagnostic intervals is to obtain valid
and complete data and, at the same time, capture the complexity of
the pathways to a diagnosis of cancer. However, this might lead to
overly cumbersome approaches and significant response burden.
Therefore, researchers should develop questions which are (1)
precise about the time point they are endeavouring to describe; (2)
applicable to both the cancer in question and the likely symptom and
symptom complexes that the patient experiences; and (3) specific
about the context of the health-care system.
Questions should be derived from a clearly stated theoretical
basis, and the health-care context should be clearly described, to
allow for appropriate interpretation of responses. Ways in which
the measurement approach takes into account multiple symptoms,
chronic symptoms and co-existent co-morbidity should be
described.
For measurement of the date of first symptom and date of first
presentation, in-depth qualitative interviews with patients are
preferred when there is a need for detailed understanding of the
time point. Strategies such as calendar landmarking (Glasner and
Van der Vaart, 2009) should be considered to reduce recall bias in
qualitative interviews. In common with research in other fields,
patient-completed surveys (typically in the form of self-completion
questionnaires) provide the best opportunity for producing large,
population-based data sets, but their limitations in capturing the
complexity of these time points should be acknowledged and
researchers should clarify how the survey has been developed in
accordance with the international standards (Mokkink et al, 2010).
For the date of first presentation, ideally, information
should be gathered from both patients and primary-care providers,
as their concepts of this time point may differ, particularly in the
context of vague, nonspecific or chronic symptoms. Open-ended
questions, while making coding more difficult, are typically needed
to encompass the complexity of cancer-related symptoms.
It is important to scrutinise the literature to be sure that projects
include the best available measurement instrument. In future, we
might see internationally validated standard questionnaires in this
field. Therefore, it is also important that researchers provide very
transparent information on development of interviews and surveys.
Case-note audit Retrospective examination of case notes (e.g.,
charts and medical records) is an important source of information
in medical research and clinical audit; a vital consideration is the
accuracy of this information (Lilford et al, 2007). This approach
should ideally be used to augment or validate data from other
sources, particularly for complex time points such as date of first
symptom. There should be a description of the process of how the
clinician makes and codes the record and how clinicians interpret
and record the patient’s history in the clinical notes. Further, the
likely completeness of the case-note data should be described.
There is typically little data in secondary case notes on early stages
of the diagnostic pathways (i.e., time points before the patient
arrives in secondary care), although they are an important source
of information on latter stages of the patient’s journey.
Primary-care database analysis There has been a growth in the
number and quality of databases, which collect encounter and
diagnostic information from primary care – one example is the
General Practice Research Database (GPRD) (Jones et al, 2009).
These offer the potential to conduct analyses on large samples and
can facilitate study designs such as retrospective cohort studies.
When used, there should be a thorough description of the database
and its capacity to capture valid information on time points
and intervals (e.g., completeness and accuracy of recording of
encounter data). Further, the limitations deriving from coding
systems used in the database should be described and there should
be the standard procedures for both conceptualising data fields
and uploading data in a standard format. In common with case-
note audit, there are limitations in deriving information on time
points, such as date of first symptom from analysis of databases,
although both audit and database analysis can be useful in deriving
information on the date of first presentation.
The Aarhus checklist
Based on these recommendations, the CWG has developed a
checklist for early diagnosis researchers. The checklist is intended
for individuals undertaking research that involves the description
and measurement of intervals in the cancer diagnostic journey.
It has been produced with the intention of promoting greater
consistency and transparency in methods and measurements.
Furthermore, it is a resource both for those developing studies that
require measurement of intervals and/or mapping of cancer
patient journeys and for journal paper reviewers, editors and
funding bodies who can use these items as a framework for
assessing the quality of research applications and papers.
DISCUSSION
We report the first comprehensive guidance for the conduct and
reporting of research in this field. We have highlighted the many
challenges and pitfalls in early diagnosis research, and call for
greater precision and transparency in both definitions and
methods. Our rigorous and multidisciplinary approach to con-
sensus development, coupled with detailed analysis of the existing
Box 2 EUROPEAN NETWORK OF CANCER REGISTRIES:
HIERARCHY FOR DEFINING THE DATE OF DIAGNOSIS (http://
www.encr.com.fr/incideng.pdf)
In the order of declining priority:
1. Date of first histological or cytological confirmation of this malignancy
(with the exception of histology or cytology at autopsy). This date should
be, in the following order:
(a) date when the specimen was taken (biopsy)
(b) date of receipt by the pathologist
(c) date of the pathology report
2. Date of admission to the hospital because of this malignancy.
3. When evaluated at an outpatient clinic only: date of first consultation at the
outpatient clinic because of this malignancy.
4. Date of diagnosis, other than 1, 2 or 3.
5. Date of death, if no information is available other than the fact that the
patient has died because of a malignancy.
6. Date of death, if the malignancy is discovered at autopsy.
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early diagnosis literature, has produced guidance that can promote
(the primary) consistency and methodological rigour in this field.
Our recommendations are relevant to researchers, funding bodies,
and journal editors and reviewers. The next step is to examine
whether these definitions and recommendations can be readily
adopted by researchers; evidence from similar previous initiatives
suggests that researchers are receptive to new methodological
guidance and that it can have a positive effect on research quality
(Willis and Quigley, 2011; Wynne et al, 2011).
Although our checklist has not addressed analytical techniques,
the choice of technique is crucial, given that analyses of time
intervals are used to monitor quality of clinical trajectories and in
research on prognosis of cancer. In prognostic research, there is
strong evidence to suggest that time-interval data should be
analysed in a statistical model using time interval as a continuous
variable, rather than a dichotomised model, in order to minimise
bias arising from what has been termed ‘the waiting time paradox’
(Crawford et al, 2002; Torring et al, 2011).
We have identified a pressing need for more methodological
work in this field and we are in the process of further evaluation
and validation of our recommendations, which can be viewed in
greater detail on the Cancer and Primary Care Research
International (Ca-PRI) Network (http://www.ca-pri.com/). Feed-
back on the guidance will be used for future updates.
CONCLUSION
There are growing international efforts to describe and measure
patient journeys prior to a cancer diagnosis. Accurate descriptions
of these patient journeys and valid measurements of diagnostic
intervals are essential to determine the effectiveness of interven-
tions to reduce them. The Aarhus checklist will facilitate the
standardised and uniform definition and reporting of studies in
this area.
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